Activation of tumor-specific T-cell response

"Activation of tumor-specific T-cell response" is not a single molecule or receptor but rather describes a biological process in which T cells that specifically recognize tumor antigens become activated. This process is central to many immunotherapy strategies for cancer. The identification and expansion of these tumor-reactive T cells—often from patient-derived tumor-infiltrating lymphocytes—are key steps in adoptive cell transfer therapies. Markers such as PD‑1, CD137, and others are used to identify these populations; drugs like nivolumab can enhance their activity by blocking inhibitory signals such as those mediated by the PD‑1/PD-L1 axis. While this approach has shown clinical benefit in cancer therapy, it is not itself a molecular target but rather an immunological outcome or therapeutic goal[1][2]. Because "Activation of tumor-specific T-cell response" refers to a process and not a discrete molecular entity such as a receptor or enzyme, it should not be classified as a canonical drug target. Instead, individual molecules involved in this process—such as Programmed cell death protein 1 (PD‑1), its ligand PD-L1/PD-L2, and costimulatory molecules like CD137—are considered true therapeutic targets[1].

Other names

Tumor-specific T cell activationTumor-reactive T cell responseActivation of tumor-infiltrating lymphocytes (TILs)

- Immune checkpoint inhibition (e.g., PD‑1/PD‑L1 blockade to restore T-cell function)[1][2] - Cytokine-mediated expansion and activation of T cells[1][2]